The Wegovy 2mg pen: what it is, when you use it, and what to expect

Wegovy's UK-licensed dose ladder runs 0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg (with a new 7.2mg maximum now approved); there is no licensed 2mg pen.
Each pen in the schedule delivers four once-weekly doses, and your prescriber decides when (and whether) to move you to the next strength.
The titration schedule exists to manage tolerability: moving too quickly increases the chance of nausea and other gastrointestinal effects.
Wegovy is a GLP-1 receptor agonist made by Novo Nordisk, licensed in the UK for weight management alongside a reduced-calorie diet and increased physical activity.

There is no dedicated Wegovy 2mg pen. Wegovy (semaglutide) is prescribed in a stepped dose schedule — 0.25mg, 0.5mg, 1mg, 1.7mg and 2.4mg — and the 2mg figure most people encounter online does not correspond to any pen in the UK-licensed range. If you've seen this dose mentioned and found yourself confused, you're not alone; it comes up often, usually because people are mixing up Wegovy with Ozempic or other semaglutide products. This page explains the actual schedule, what each pen contains, and how the titration process works, so you have accurate information before speaking to a prescriber. Like all Wegovy pens, these are prescription-only medicines that require a clinical assessment before they can be dispensed.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

How the Wegovy dose schedule actually works, and where confusion about a '2mg' pen comes from

Why does a 'Wegovy 2mg pen' keep appearing in searches?

The short answer is: confusion between products. Semaglutide exists under several brand names in the UK, and not all of them are licensed for weight loss. Ozempic is also semaglutide, but it is licensed for type 2 diabetes management (not weight management) and it comes in 0.25mg, 0.5mg, 1mg and 2mg pens. That 2mg Ozempic pen is likely the origin of much of the search traffic around 'Wegovy 2mg'. The two products share an active ingredient but have different licensed indications, different dose ceilings, and different approval histories in the UK. A prescriber treating you for weight loss through a regulated service will work from the Wegovy schedule, not the Ozempic one. If you're thinking about semaglutide for weight management, the relevant pens start at 0.25mg and work upward over several months. The NHS medicines page for semaglutide sets out both products and their distinct licensed uses clearly, and is a good reference point before you dig further.

What pens does the actual Wegovy schedule include?

Wegovy's UK-licensed titration pathway uses five strengths: 0.25mg for the first four weeks, stepping up to 0.5mg, then 1mg, then 1.7mg, with 2.4mg as the standard maintenance dose. Novo Nordisk's Wegovy pen range covers each of these steps. In January 2026 the MHRA also approved a 7.2mg maintenance dose (initially supplied as three 2.4mg pens weekly) and a dedicated single-dose 7.2mg pen followed in April 2026, expanding the ceiling for people who need it. Each pen in the schedule is pre-filled and delivers four once-weekly injections before it's used up. A separate pen is prescribed for each dose stage. The 1mg pen, for example, is its own product; some people refer to it as the Wegovy 1mg pen to distinguish it from neighbouring strengths. If you'd like a fuller breakdown of pen sizes and the volume each contains, the Wegovy pen in millilitres page covers that detail. The key practical point is that moving between strengths is a clinical decision, not a personal one, your prescriber reviews your response and tolerance before authorising the next step.

Does the 1.7mg or 2.4mg pen get misread as a '2mg' dose?

It's possible. The 1.7mg pen sits just below 2mg numerically, and the 2.4mg maintenance pen is the closest Wegovy comes to a round 2mg figure. Neither is described as 2mg in its licensed documentation, but in informal conversation or imprecise online summaries the numbers blur. This matters because dose precision is not a minor detail for a prescription medicine. The Wegovy 4mg pen is another common search, it also does not exist in the current licensed schedule, for the same reason: Wegovy's strengths are set by Novo Nordisk's approved SmPC, not rounded to convenient integers. If you have questions about which pen you're currently on, or what comes next, your prescriber is the right person to ask. Our step-by-step guide to using Wegovy covers injection technique, site rotation and storage for people already in treatment.

What should you do if you're looking for semaglutide for weight management?

The first step is a clinical assessment. Wegovy is a prescription-only medicine; it cannot legally be dispensed without one, and any seller offering it without that process is operating outside UK law. The MHRA has issued repeated warnings about counterfeit injectable pens sold online, some of which have contained entirely different substances. Verifying that a pharmacy is GPhC-registered before placing any order is a straightforward safety check, the GPhC register is publicly searchable. At nume, a GPhC-registered Independent Prescriber reads every consultation the same day. There are no automated approvals. If Wegovy is clinically appropriate for you, treatment is dispatched the same day an order is placed before 12pm and arrives the next working day via tracked DPD delivery, in plain unbranded packaging. You can read more about where to get Wegovy in the UK and what to look for in a legitimate provider, or explore the full range of weight-loss treatment options if you're still deciding which route suits you. The cost of private treatment varies by provider and dose; the treatment page shows what's included at nume, consultation, prescription, delivery and 7-day aftercare, no subscription, no hidden fees. If you're ready to take the next step, checking your eligibility starts there.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions